Pneumococcal conjugate vaccines as maternal and infant immunogens: Challenges of maternal recruitment

Vaccine

Volumn 21, Issue 24, 2003, Pages 3473-3478

  Daly, Kathleen A ^a   Toth, Julie A ^b   Giebink, G Scott ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Otitis media; Pneumococcal

Indexed keywords

ANTIGEN; PLACEBO; PNEUMOCOCCUS VACCINE;

ADULT; ANTIBODY PRODUCTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; IMMUNIZATION; INDUSTRIALIZATION; INFANT; NORMAL HUMAN; OTITIS MEDIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND TRIMESTER PREGNANCY; SIDE EFFECT; STREPTOCOCCUS INFECTION;

EID: 0038449125     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00354-2     Document Type: Conference Paper

References (22)

1. Kraemer M.J., Richardson M.A., Weiss N.S.et al. Risk factors for persistent middle-ear effusions. Otitis media, catarrh, cigarette smoke exposure and atopy. JAMA. 249:1983;1022-1025.
2. Teele DW, Klein JO, Rosner B, Greater Boston Otitis Media Study Group. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective cohort study. J Infect Dis 1989;160:83-94.
3. Gates G.A. Cost-effectiveness considerations in otitis media treatment. Otolaryngol. Head Neck Surg. 114:1996;525-530.
4. Dowell S.F., Butler J.C., Giebink G.S.et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr. Infect. Dis. J. 18:1999;1-9.
5. World Health Organization. Pneumococcal vaccines - WHO position paper. Wkly Epidemiol Rec 1999;74:177-84.
6. Juvén T., Mertsola J., Waris M.et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr. Infect. Dis. J. 19:2000;293-298.
7. Gendrel D., Raymond J., Moulin F.et al. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Eur. J. Clin. Microbiol. Infect. Dis. 16:1997;388-391.
8. Black S., Shinefield H., Fireman B.et al. Efficacy safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:2000;187-195.
9. Dagan R., Melamed R., Muallem M.et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J. Infect. Dis. 174:1996;1271-1278.
10. Dagan R., Fraser D. Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. Pediatr. Infect. Dis. J. 19:2000;S79-S88.
11. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180:1999;1171-1176.
12. Eskola J., Kilpi T., Palmu A.et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:2001;403-409.
13. Kilpi T, Palmu A, Leinonen M, Eskola J, Firom SG. Efficacy of a seven-valent pneumococcal conjugate vaccine (PncOMPC) against serotype-specific acute otitis media caused by Streptococcus pneumoniae (Pnc). In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2000. Toronto, Canada: American Society for Microbiology; 2000. p. 245 [abstract 689].
14. Rennels M.B., Edwards K.M., Keyserling H.L.et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 101:1998;604-611.
15. Glezen W.P. Editorial: prevention of neonatal tetanus. Am. J. Public Health. 88:1998;871-872.
16. Hajek D., Quartey M.K., Giebink G.S. Maternal pneumococcal conjugate immunization protects infant chinchillas in the pneumococcal otitis media model. Acta Otolaryngol. 122:2002;262-269.
17. Freid V.M., Mukuc D.M., Rooks R.N. Ambulatory health care visits by children: principal diagnosis and place of visit. Vital Health Stat. 13:1998;1-23.
18. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(no. RR-4):1-29.
19. Insel R.A., Amstey M., Woodin K., Pichichero M. Maternal immunization to prevent infectious diseases in the neonate or infant. Intl. J. Technol. Assess. Health Care. 10:1994;143-153.
20. Shahid N.S., Steinhoff M.C., Hoque S.S., Begum T., Thompson C., Siber G.R. Serum, breast milk, and infant antibody after maternal immunization with pneumococcal vaccine. Lancet. 346:1995;1252-1257.
21. Munoz F.M., Englund J.A., Cheesman C.C.et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine. 20:2001;826-837.
22. O'Dempsey T.J., McArdle T., Ceesay S.J.et al. Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine. 14:1996;963-970.